A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by ARCAGY/ GINECO GROUP
Sponsor:
Information provided by (Responsible Party):
ARCAGY/ GINECO GROUP
ClinicalTrials.gov Identifier:
NCT01111903
First received: April 26, 2010
Last updated: January 9, 2014
Last verified: January 2014
  Purpose

Study in two stages, and with a sub-study.


Condition Intervention Phase
Ovarian Cancer Recurrent
Drug: Lenalidomide
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Two Stage Trial of lénalidomide (Revlimid®) : a Phase II Study of lénalidomide as Single Agent in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse: Followed by a Phase I of lénalidomide in Combination With Carboplatin and Liposomal Pegylated Doxorubicin.

Resource links provided by NLM:


Further study details as provided by ARCAGY/ GINECO GROUP:

Primary Outcome Measures:
  • Efficacy of lenalidomide as single agent, then DMT of lenalidomise with carboplatin and pegylated liposomal doxorubicin [ Time Frame: Rate of Tumor Response + Stable Disease (at 4 months) / DMT ] [ Designated as safety issue: Yes ]

    STAGE A: To determine efficacy of lenalidomide as single agent in patients with recurrent ovarian cancer in second or third line.

    STAGE B: To determine the Maximum Tolerated Dose (MTD) of lenalidomide in combination with chemotherapy consisting of carboplatin and pegylated liposomal doxorubicin.



Secondary Outcome Measures:
  • Safety profile of lenalidomide as single agent, then in combination [ Time Frame: Response rate, Stable Disease rate at 4 months / MDT ] [ Designated as safety issue: Yes ]

    STAGE A:

    • To determine the safety profile of lenalidomide (type, frequency, severity, and relationship of adverse events to study treatment).
    • To assess time to progression (TTP).

    STAGE B:

    • To evaluate the safety profile of the combination therapy.
    • To determine the response rate.
    • To assess time to progression.


Estimated Enrollment: 72
Study Start Date: May 2009
Estimated Study Completion Date: October 2014
Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: lenalidomide
Phase II: lenalidomide 20 mg/day in continuous regimen. Phase I: lenalidomide 25 mg/day 21 days/28 + carboplatin AUC 5 + caelyx 30 mg/m2
Drug: Lenalidomide
Phase II: 20 mg/day in continuous regimen Phase I: 25 mg/day 21 days/28 with carboplatine AUC 5 + caelyx 30mg/m2

Detailed Description:

Stage A: To determine efficacy of lenalidomide as single agent in patients with recurrent ovarian cancer in second or third line.

Stage B: To determine the Maximum Tolerated Dose (MTD) of lenalidomide in combination with chemotherapy consisting of carboplatin and pegylated liposomal doxorubicin.

Substudy: To investigate the impact of the lenalidomide on patients' immune system affected by cancer and to look for an immunizing marker which could be predictive of the activity of the lenalidomide in the solid tumors.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Stage A: Patient:

  • aged > 18 years.
  • with a histological proven diagnosis of epithelial cancer of the ovary, the fallopian tube or extra-ovarian papillary serous tumors.
  • with asymptomatic disease in progression detected by increase of CA 125 levels according to GCIG criteria during systematic follow-up, with or without measurable lesions.
  • with disease in progression > 6 months after a first or second line including a platinum derivative. Patients should have received previously a taxane derivative.
  • Adequate bone marrow, renal and hepatic function defined as: . WBC > 3.0 x 109/L or Neutrophils (ANC) > 1,5 x 109/L; Platelets > 100 x 109/L; Hemoglobin > 6 mmol/L (10,0 mg/dL); Bilirubin < 2 x upper normal limit of normal range; Estimated glomerular filtration rate > 50 ml/mn according to Cockroft-Gault formula.
  • with ECOG performance status = 0 or 1.
  • with a life expectancy of at least 16 weeks
  • who have given their signed and written informed consent to participate in the trial after fully understanding the implication and constraints of the protocol.

Stage B: Patients

  • aged > 18 years.
  • with a histological proven diagnosis of epithelial cancer of the ovary, the fallopian tube or extra-ovarian papillary serous tumors.
  • with disease in progression > 6 months after a first or second line including a platinum derivative. patients should have received previously a taxane derivative.
  • Measurable disease by RECIST or evaluable disease by GCIG (CA-125).
  • Patients included in stage A with disease in progression under lenalidomide could be eligible in phase B if they did not experience unacceptable toxicity under lenalidomide in stage A. Patients should stop lenalidomide for 7 days before entry in stage B (7 days wash out).
  • Adequate bone marrow, renal and hepatic function defined as: . WBC > 3.0 x 109/L or Neutrophils (ANC) > 1,5 x 109/L; Platelets > 100 x 109/L; Hemoglobin > 6 mmol/L (10,0 mg/dL); Bilirubin < 2 x upper normal limit of normal range; Estimated glomerular filtration rate > 50 ml/mn according to Cockroft-Gault formula.
  • with LVEF under normal range
  • with ECOG performance status = 0 or 1.
  • with a life expectancy of at least 16 weeks.
  • who have given their signed and written informed consent to participate in the trial after fully understanding the implication and constraints of the protocol.

Exclusion Criteria:

  • Ovarian tumors of low malignant potential (borderline tumors).
  • Non-epithelial ovarian or mixed epithelial/non epithelial tumors (e.g. mixed Mullerian tumors).
  • Patients with a prior diagnosis of any malignancy not cured by surgery alone less than 5 years before study entry (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin).
  • Patients who have received previous radiotherapy.
  • Presence of symptomatic brain metastases.
  • Patients with a history of seizure disorder or central nervous system disorders; pre-existing motor or sensory neurologic pathology or symptoms > NCI-CTC grade 1.
  • History of congestive heart failure (NYHA Classification > 2, even if medically controlled. History of clinical and electrocardiographically documented myocardial infarction within the last 6 months. History of atrial or ventricular arrhythmias (≥ LOWN II).
  • Thrombosis or anti-thrombosis treatment within 6 months.
  • History of visceral bleeding, gastrointestinal ulcer in 6 months.
  • Obstructive or sub-occlusive disease.
  • Patients with severe active infection.
  • Concurrent severe medical problems unrelated to malignancy which would significantly limit full compliance with the study or expose the patient to extreme risk or decreased life expectancy.
  • Fertile women not using adequate contraceptive methods, or who are pregnant or breast feeding.
  • Histories of allergy or sentimentality known about the similar chemical compounds in the carboplatine, either in the doxorubicine liposomale pégylée, or in one of the constituents of the lenalidomide.
  • Patient having developed a knotty erythema characterized by a rash with desquamation during grip(taking) of thalidomide or a medicine similaire.
  • Previous administration of lenalidomide.
  • Seropositivity known about the virus of the human immunodeficiency (HIV), or pathology bound to the syndrome of acquired immunodeficiency (AIDS) or hepatitis activates type A, B or C.
  • Administration of other simultaneous chemotherapeutic drugs, or hormonal therapy, or simultaneous radiotherapy during the study treatment period (hormone replacement therapy is allowed as are steroid antiemetics).
  • Dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01111903

Locations
France
Hopital Tenon Recruiting
Paris, France, 75020
Contact: Frederic Selle, Dr    +33 1 56 01 60 21    frederic.selle@tnn.ap-hop-paris.fr   
Principal Investigator: Frederic Selle, Dr         
Sponsors and Collaborators
ARCAGY/ GINECO GROUP
Investigators
Principal Investigator: Frédéric SELLE, MD Hôpital Tenon
  More Information

No publications provided

Responsible Party: ARCAGY/ GINECO GROUP
ClinicalTrials.gov Identifier: NCT01111903     History of Changes
Other Study ID Numbers: REV (GINECO-OV214)
Study First Received: April 26, 2010
Last Updated: January 9, 2014
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Ovarian Diseases
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Lenalidomide
Thalidomide
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors

ClinicalTrials.gov processed this record on July 20, 2014